The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Insulet has launched the Omnipod 5 automated insulin delivery app for iPhone in the US. The app obviates the need for carrying a separate controller as it allows users to manage their insulin ...

As Insulet continues on its path to roll out its next-generation wearable insulin pump this year—and just after passing the $1 billion annual sales mark—the diabetes management company is making a ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

The FDA has cleared the first tubeless automated insulin delivery system with a smartphone app control. The FDA has cleared Insulet’s Omnipod 5 automated insulin delivery system, marking the first ...

Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

Insulet is bringing a splash of color to the diabetes technology market. Working with Pantone, the insulin pump company has created the “bright and joyful tropical orange yellow” color Omnipod Mango.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod ...

InsuletPODD stock hit a new high of 337.26 on Thursday. Shares are in a buy zone. The IBD Sector Leader makes the Omnipod insulin pump for people with diabetes. Insulet is expanding the use of its ...

Insulet Corporation PODD reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked a ...